Johnson & Johnson shares are climbing on Tuesday after posting an all-round first-quarter beat. The healthcare giant posted earnings of $1.54 a share -- that was $0.06 higher than analysts expected and nearly 7% higher year over year. The higher profits stemmed from strong sales growth in its prescription drugs segment, which soared 11% over the quarter. As for total revenue, that grew 3.5% year on year to $18.1 billion, around $111 million over analysts' expectations.